Who is sponsoring NCT02136147?

NCT02136147 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT02136147?

Interventions in NCT02136147: methylphenidate medication, atomoxetine medication, lisdexamphetamine medication, guanfacine medication.

What condition does NCT02136147 study?

NCT02136147 studies Attention Deficit Disorder With Hyperactivity (ADHD).

Is NCT02136147 still recruiting?

NCT02136147 is currently completed. Last updated 16 October 2023.

Last reviewed 2023-10-16 · How we verify

NCT02136147: ADAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome

Completed Last updated 16 October 2023

What this trial tests

trial testing methylphenidate medication in Attention Deficit Disorder With Hyperactivity (ADHD) in 632 participants. Completed in 1 June 2022.

Timeline

1 June 2015

Primary endpoint
1 July 2021

1 June 2022

Quick facts

Lead sponsor	Karolinska Institutet
Status	Completed
Study type	OBSERVATIONAL
Enrollment	632
Start date	1 June 2015
Primary completion	1 July 2021
Estimated completion	1 June 2022
Sites	1 location across Sweden

Drugs / interventions tested

methylphenidate medication — full drug profile →
atomoxetine medication — full drug profile →
lisdexamphetamine medication — full drug profile →
guanfacine medication — full drug profile →

Conditions studied

Attention Deficit Disorder With Hyperactivity (ADHD) — all drugs for Attention Deficit Disorder With Hyperactivity (ADHD) →

Sponsor

Karolinska Institutet

Who can join

Adults 6 to 18, any sex, with Attention Deficit Disorder With Hyperactivity (ADHD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale)
Time frame: at 3 months follow-up
ADHD symptoms
change in P-SEC (Pediatric Side Effects Checklist)
Time frame: at 3 months follow-up
Side-effect measure

Sponsor's own description

ADHD medication of children and adolescents is becoming increasingly common. Clinical experience and scientific studies have proven that approximately 30% of children/adolescents with ADHD do not benefit from this treatment. However, there is insufficient knowledge about who these children are. All children and adolescents, who start treatment with ADHD medication at public Child and Adolescent Psychiatry units in Stockholm, on Gotland, an in Västerbotten, will be asked to participate in the study. The investigators intend to monitor the patients´clinical symptoms and possible side-effects after treatment start. The investigators will collect background information and saliva samples from the patient and his/her parents to be able to study if there are any genetic (hereditary) or other markers that can predict positive or negative outcomes of the ADHD medication. With this information, the investigators aim at, to a greater extent, be able to individualize treatment choices for children and adolescents with ADHD without unnecessary, costly and possibly unfavorable treatment attempts.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort.
Lilja MM, Sandblom E, Lichtenstein P, Serlachius E, et al · · 2022 · cited 9× · PMID 35249540 · DOI 10.1186/s11689-022-09424-2
Can response to ADHD medication be predicted?
Lilja MM, Lichtenstein P, Serlachius E, Bhagia J, et al · · 2025 · cited 5× · PMID 39875602 · DOI 10.1007/s00787-025-02650-8

Verify or expand the search:

Other recruiting trials for Attention Deficit Disorder With Hyperactivity (ADHD)

Currently open trials in the same condition.

NCT07217652 — Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility · NA · recruiting
NCT06743763 — fNIRS-Based Neurofeedback Training in Children With ADHD: The Effects of VR · NA · recruiting

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02136147 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 16 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02136147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing